SG Americas Securities LLC Purchases 9,260 Shares of Halozyme Therapeutics, Inc. $HALO

SG Americas Securities LLC grew its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 35.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 35,093 shares of the biopharmaceutical company’s stock after purchasing an additional 9,260 shares during the quarter. SG Americas Securities LLC’s holdings in Halozyme Therapeutics were worth $2,362,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Root Financial Partners LLC acquired a new stake in Halozyme Therapeutics during the 3rd quarter worth $25,000. Larson Financial Group LLC boosted its position in shares of Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 343 shares during the last quarter. Richardson Financial Services Inc. grew its stake in shares of Halozyme Therapeutics by 87.6% during the third quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 198 shares during the period. Newbridge Financial Services Group Inc. bought a new stake in Halozyme Therapeutics in the second quarter valued at about $32,000. Finally, Clearstead Advisors LLC lifted its stake in Halozyme Therapeutics by 107.7% in the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 265 shares during the period. 97.79% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. TD Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, January 29th. Weiss Ratings downgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research note on Tuesday, February 24th. Benchmark lifted their price target on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. Finally, Wells Fargo & Company upped their price objective on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research report on Thursday, February 19th. Six research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $78.56.

Halozyme Therapeutics Price Performance

HALO stock opened at $64.49 on Friday. The stock has a 50-day moving average price of $69.94 and a two-hundred day moving average price of $69.33. Halozyme Therapeutics, Inc. has a 1 year low of $47.50 and a 1 year high of $82.22. The stock has a market cap of $7.64 billion, a PE ratio of 25.90, a price-to-earnings-growth ratio of 0.26 and a beta of 1.03. The company has a current ratio of 4.66, a quick ratio of 3.66 and a debt-to-equity ratio of 43.89.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of $1.92 by ($2.16). Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The firm had revenue of $451.77 million for the quarter, compared to analyst estimates of $446.13 million. During the same period in the prior year, the company earned $1.26 earnings per share. The firm’s quarterly revenue was up 51.6% on a year-over-year basis. Equities analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 2,000 shares of the stock in a transaction on Monday, January 5th. The shares were sold at an average price of $70.25, for a total transaction of $140,500.00. Following the completion of the transaction, the director owned 40,123 shares in the company, valued at approximately $2,818,640.75. This represents a 4.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Cortney Caudill sold 8,857 shares of the business’s stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $67.64, for a total transaction of $599,087.48. Following the sale, the chief operating officer directly owned 7,055 shares in the company, valued at $477,200.20. This trade represents a 55.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 110,857 shares of company stock valued at $7,785,087 over the last 90 days. 2.40% of the stock is owned by corporate insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.